Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression
Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression
novocure報告臨牀資料來自第3期METIS試驗的介紹。試驗達成了主要終點，顯示對顱內進展時間有顯著的統計改善。
Patients treated with TTFields therapy and BSC exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with BSC alone (hazard ratio=0.67; P=0.016). Median TTFields therapy duration was 16 weeks and median usage was 67%. Baseline patient demographics and characteristics were well balanced between arms.
接受TTFields療法和BSC治療的患者與僅接受BSC治療的患者相比，顱內進展的中位時間爲21.9個月，而BSC組爲11.3個月(危險比=0.67; P=0.016)。TTFields療法的中位治療時間爲16周，使用率爲67%。基線患者人口統計學和特徵在各組之間平衡。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間